- Home
- LGHL vs OGEN Comparison
LGHL vs OGEN Comparison
Compare LGHL & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGHL
- OGEN
- Stock Information
- Founded
- LGHL 2015
- OGEN 1996
- Country
- LGHL Singapore
- OGEN United States
- Employees
- LGHL N/A
- OGEN N/A
- Industry
- LGHL Investment Bankers/Brokers/Service
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- LGHL Finance
- OGEN Health Care
- Exchange
- LGHL Nasdaq
- OGEN Nasdaq
- Market Cap
- LGHL 1.2M
- OGEN 1.2M
- IPO Year
- LGHL N/A
- OGEN N/A
- Fundamental
- Price
- LGHL $1.45
- OGEN $1.05
- Analyst Decision
- LGHL
- OGEN
- Analyst Count
- LGHL 0
- OGEN 0
- Target Price
- LGHL N/A
- OGEN N/A
- AVG Volume (30 Days)
- LGHL 1.3M
- OGEN 110.3K
- Earning Date
- LGHL 09-12-2025
- OGEN 08-08-2025
- Dividend Yield
- LGHL N/A
- OGEN N/A
- EPS Growth
- LGHL N/A
- OGEN N/A
- EPS
- LGHL N/A
- OGEN N/A
- Revenue
- LGHL N/A
- OGEN N/A
- Revenue This Year
- LGHL N/A
- OGEN N/A
- Revenue Next Year
- LGHL N/A
- OGEN N/A
- P/E Ratio
- LGHL N/A
- OGEN N/A
- Revenue Growth
- LGHL N/A
- OGEN N/A
- 52 Week Low
- LGHL $1.43
- OGEN $1.02
- 52 Week High
- LGHL $20.86
- OGEN $38.70
- Technical
- Relative Strength Index (RSI)
- LGHL 30.08
- OGEN 30.89
- Support Level
- LGHL $1.44
- OGEN $1.03
- Resistance Level
- LGHL $2.40
- OGEN $1.13
- Average True Range (ATR)
- LGHL 0.26
- OGEN 0.05
- MACD
- LGHL -0.02
- OGEN 0.04
- Stochastic Oscillator
- LGHL 11.57
- OGEN 15.06
About LGHL Lion Group Holding Ltd.
Lion Group Holding Ltd is an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, Hong Kong-based Over-The-Counter (OTC) stock options trading business, and futures and securities brokerage services. It provides these services through its Lion Brokers Pro and a variety of other applications. The company generates a majority of its revenue from its CFD trading services business. Geographically, the firm's key revenue-generating market is Hong Kong.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.